Abstract
Although reports of antimalarial drug resistance emerged as early as 1910 from South America, the first event that really had a major impact on malaria control and drug development was the emergence of chloroquine resistance in the 2nd half of the 20th century. The appearance of resistance to chloroquine has marked the onset of a race between the development of ever new generations of antimalarial drugs and the emergence of resistance to these antimalarials, finally culminating in the emergence of clinical artemisinin resistance which was first reported in 2008. The potentially devastating impact of resistance to a drug that has been adopted as the first line drug for the treatment of uncomplicated falciparum malaria by virtually all malaria control programs throughout the malaria-endemic world, and for which there currently is no successor in sight should it truly fall victim to widespread drug resistance, calls for strategies to extend the useful life spans of currently available antimalarial drugs while at the same time stepping up efforts to develop novel combination therapies not based on artemisinins.
Keywords: Therapy, Plasmodium falciparum malaria, artemisinin-based combination therapy, artemisinin resistance, combination therapy
Current Pharmaceutical Design
Title:The Need for New Antimalarial Drugs Less Prone to Resistance
Volume: 19 Issue: 2
Author(s): Harald Noedl
Affiliation:
Keywords: Therapy, Plasmodium falciparum malaria, artemisinin-based combination therapy, artemisinin resistance, combination therapy
Abstract: Although reports of antimalarial drug resistance emerged as early as 1910 from South America, the first event that really had a major impact on malaria control and drug development was the emergence of chloroquine resistance in the 2nd half of the 20th century. The appearance of resistance to chloroquine has marked the onset of a race between the development of ever new generations of antimalarial drugs and the emergence of resistance to these antimalarials, finally culminating in the emergence of clinical artemisinin resistance which was first reported in 2008. The potentially devastating impact of resistance to a drug that has been adopted as the first line drug for the treatment of uncomplicated falciparum malaria by virtually all malaria control programs throughout the malaria-endemic world, and for which there currently is no successor in sight should it truly fall victim to widespread drug resistance, calls for strategies to extend the useful life spans of currently available antimalarial drugs while at the same time stepping up efforts to develop novel combination therapies not based on artemisinins.
Export Options
About this article
Cite this article as:
Noedl Harald, The Need for New Antimalarial Drugs Less Prone to Resistance, Current Pharmaceutical Design 2013; 19 (2) . https://dx.doi.org/10.2174/1381612811306020266
DOI https://dx.doi.org/10.2174/1381612811306020266 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Pediatric Reviews Water Mapping and Scoring Approaches to Predict the Role of Hydration Sites in the Binding Affinity of PAK1 Inhibitors
Combinatorial Chemistry & High Throughput Screening The Zinc Metallopeptidase Family: New Faces, New Functions
Protein & Peptide Letters Peptide-based Vaccines in the Treatment of Specific Allergy
Current Drug Targets - Inflammation & Allergy Repurposing Ruxolitinib in Combating COVID-19: A Mini-review
New Emirates Medical Journal Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Mechanism of Action of Chloroquine/Hydroxychloroquine for Covid-19 Infection
Coronaviruses Decision Tree Methods in Pharmaceutical Research
Current Topics in Medicinal Chemistry Correlation of Indeterminate Lesions of COVID-19 Pneumonia Detected on Computed Tomography with RT-PCR Results
Current Medical Imaging Synthesis and Biological Evaluation of 3-cyano-4H-chromene Derivatives Bearing Carbamate Functionality
Medicinal Chemistry Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews Thematic Analysis™ : A Chemogenomic Approach to GPCR Drug Discovery
Current Topics in Medicinal Chemistry QSAR and 3D-QSAR Models in the Field of Tubulin Inhibitors as Anticancer Agents
Current Topics in Medicinal Chemistry Review Camptothecin: Current Perspectives
Current Medicinal Chemistry Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold
Medicinal Chemistry Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Mini-Reviews in Medicinal Chemistry Stem Cell-Based Approaches for Intervertebral Disc Regeneration
Current Stem Cell Research & Therapy Fullerenes in Medicinal Chemistry and their Biological Applications
Mini-Reviews in Medicinal Chemistry